Both Moleculin Biotech Inc. (NASDAQ:MBRX) and PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech Inc.	N/A	0.00	12.28M	-0.51	0.00
PhaseBio Pharmaceuticals Inc.	N/A	173.75	21.51M	-1.02	0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Moleculin Biotech Inc. and PhaseBio Pharmaceuticals Inc.

Profitability

Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech Inc.	0.00%	-70.7%	-54.9%
PhaseBio Pharmaceuticals Inc.	0.00%	0%	0%

Liquidity

3 and 3 are the respective Current Ratio and a Quick Ratio of Moleculin Biotech Inc. Its rival PhaseBio Pharmaceuticals Inc.’s Current and Quick Ratios are 3.2 and 3.2 respectively. PhaseBio Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Moleculin Biotech Inc.

Insider & Institutional Ownership

The shares of both Moleculin Biotech Inc. and PhaseBio Pharmaceuticals Inc. are owned by institutional investors at 10.3% and 52.36% respectively. Insiders owned roughly 25.51% of Moleculin Biotech Inc.’s shares. Comparatively, 0.1% are PhaseBio Pharmaceuticals Inc.’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Moleculin Biotech Inc.	-6.11%	-1.6%	-25%	-33.87%	-34.57%	-33.87%
PhaseBio Pharmaceuticals Inc.	28.77%	-28.18%	0%	0%	0%	-26.6%

For the past year PhaseBio Pharmaceuticals Inc. has weaker performance than Moleculin Biotech Inc.

Summary

PhaseBio Pharmaceuticals Inc. beats on 5 of the 7 factors Moleculin Biotech Inc.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company has an agreement with Mayo Clinic to enable additional research on its WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. It also has a strategic collaboration with the University of Bergen to develop immune stimulation drug, as well as to expand research on inhibition of brain metastasis by MoleculinÂ’s pre-clinical drug WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. It is also developing PB1046, a fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is based in Malvern, Pennsylvania.